BR0013219A - Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto - Google Patents
Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produtoInfo
- Publication number
- BR0013219A BR0013219A BR0013219-5A BR0013219A BR0013219A BR 0013219 A BR0013219 A BR 0013219A BR 0013219 A BR0013219 A BR 0013219A BR 0013219 A BR0013219 A BR 0013219A
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- inhibiting
- nsaid
- kinase inhibitor
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"MéTODOS DE TRATAMENTO OU INIBIçãO DE PóLIPOS DE CóLON, DE TRATAMENTO OU INIBIçãO DE CâNCER COLORRETAL, USO DE UMA COMBINAçãO DE NSAID E DE UM INIBIDOR DE EGFR QUINASE, COMPOSIçãO FARMACêUTICA, E, PRODUTO". Esta invenção provê um método de tratamento ou inibição de pólipos do cólon ou de tratamento ou inibição de câncer colorretal em um mamífero em necessidade do mesmo, que compreende administrar ao referido mamífero um NSAID e um inibidor de quinase de EFGR.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37326199A | 1999-08-12 | 1999-08-12 | |
PCT/US2000/021021 WO2001012227A1 (en) | 1999-08-12 | 2000-08-02 | Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0013219A true BR0013219A (pt) | 2002-04-23 |
Family
ID=23471660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0013219-5A BR0013219A (pt) | 1999-08-12 | 2000-08-02 | Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1202746B1 (pt) |
JP (1) | JP2003507342A (pt) |
KR (1) | KR20020018201A (pt) |
CN (1) | CN1229142C (pt) |
AR (1) | AR029763A1 (pt) |
AT (1) | ATE341341T1 (pt) |
AU (1) | AU783116B2 (pt) |
BR (1) | BR0013219A (pt) |
CA (1) | CA2380904C (pt) |
CZ (1) | CZ2002474A3 (pt) |
DE (1) | DE60031127T2 (pt) |
DK (1) | DK1202746T3 (pt) |
EA (1) | EA006876B1 (pt) |
ES (1) | ES2272305T3 (pt) |
HK (1) | HK1042244A1 (pt) |
HU (1) | HUP0203162A3 (pt) |
IL (1) | IL147913A0 (pt) |
MX (1) | MXPA02001448A (pt) |
NO (1) | NO20020663L (pt) |
NZ (1) | NZ517120A (pt) |
PL (1) | PL353267A1 (pt) |
PT (1) | PT1202746E (pt) |
WO (1) | WO2001012227A1 (pt) |
ZA (1) | ZA200201156B (pt) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
US6384051B1 (en) | 2000-03-13 | 2002-05-07 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
ATE308364T1 (de) * | 2000-03-13 | 2005-11-15 | Wyeth Corp | Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen |
EP1412367A4 (en) | 2001-06-21 | 2006-05-03 | Ariad Pharma Inc | NEW CHINOLINE AND ITS USE |
JP4326328B2 (ja) | 2001-07-16 | 2009-09-02 | アストラゼネカ アクチボラグ | キノリン誘導体及びそれらのチロシンキナーゼ阻害薬としての使用 |
WO2003035047A2 (en) * | 2001-10-25 | 2003-05-01 | Novartis Ag | Combinations comprising a selective cyclooxygenase-2 inhibitor |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
ATE360015T1 (de) | 2002-07-31 | 2007-05-15 | Critical Outcome Technologies | Protein tyrosin kinase inhibitoren |
EP1551824B1 (en) | 2002-10-09 | 2007-12-12 | Critical Outcome Technologies, Inc. | Protein tyrosine kinase inhibitors |
AU2003295598B2 (en) * | 2002-11-15 | 2009-12-24 | Genomic Health, Inc. | Gene expression profiling of EGFR positive cancer |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
TW200529846A (en) | 2004-02-20 | 2005-09-16 | Wyeth Corp | 3-quinolinecarbonitrile protein kinase inhibitors |
MY143225A (en) | 2004-04-02 | 2011-03-31 | Osi Pharm Inc | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
JP4205757B2 (ja) | 2004-05-06 | 2009-01-07 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 4−フェニルアミノ−キナゾリン−6−イル−アミド |
NZ551431A (en) | 2004-06-03 | 2010-04-30 | Hoffmann La Roche | Treatment with cisplatin and an EGFR-inhibitor |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
US8575164B2 (en) | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
US8138191B2 (en) | 2007-01-11 | 2012-03-20 | Critical Outcome Technologies Inc. | Inhibitor compounds and cancer treatment methods |
EP2118075A1 (de) | 2007-02-06 | 2009-11-18 | Boehringer Ingelheim International GmbH | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
WO2009079797A1 (en) | 2007-12-26 | 2009-07-02 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
EA019709B1 (ru) | 2008-02-07 | 2014-05-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Спирогетероциклы и их применение в качестве лекарственных средств |
EA019183B1 (ru) | 2008-05-13 | 2014-01-30 | Астразенека Аб | Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина |
EP2283020B8 (en) | 2008-05-19 | 2012-12-12 | OSI Pharmaceuticals, LLC | Substituted imidazopyr-and imidazotri-azines |
WO2010015522A1 (de) | 2008-08-08 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
PL387312A1 (pl) * | 2009-02-19 | 2010-08-30 | Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością | Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi |
JP2012520893A (ja) | 2009-03-18 | 2012-09-10 | オーエスアイ・ファーマシューティカルズ,エルエルシー | Egfr阻害薬及びigf−1r阻害剤の投与を含む組み合わせ癌治療 |
CA2752826A1 (en) | 2009-04-20 | 2010-10-28 | OSI Pharmaceuticals, LLC | Preparation of c-pyrazine-methylamines |
WO2011120153A1 (en) | 2010-04-01 | 2011-10-06 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
EP2713736B1 (en) * | 2011-06-01 | 2023-08-02 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL135900A0 (en) * | 1997-11-04 | 2001-05-20 | Pfizer Prod Inc | Indazole bioisostere replacement of catechol in therapeuticaly active compounds |
NZ503991A (en) * | 1997-11-06 | 2001-11-30 | American Cyanamid Co | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
-
2000
- 2000-08-02 CZ CZ2002474A patent/CZ2002474A3/cs unknown
- 2000-08-02 AT AT00950930T patent/ATE341341T1/de not_active IP Right Cessation
- 2000-08-02 KR KR1020027001817A patent/KR20020018201A/ko not_active Application Discontinuation
- 2000-08-02 CN CNB008117977A patent/CN1229142C/zh not_active Expired - Fee Related
- 2000-08-02 JP JP2001516570A patent/JP2003507342A/ja active Pending
- 2000-08-02 PL PL00353267A patent/PL353267A1/xx not_active Application Discontinuation
- 2000-08-02 DE DE60031127T patent/DE60031127T2/de not_active Expired - Lifetime
- 2000-08-02 DK DK00950930T patent/DK1202746T3/da active
- 2000-08-02 ES ES00950930T patent/ES2272305T3/es not_active Expired - Lifetime
- 2000-08-02 BR BR0013219-5A patent/BR0013219A/pt not_active IP Right Cessation
- 2000-08-02 HU HU0203162A patent/HUP0203162A3/hu unknown
- 2000-08-02 EP EP00950930A patent/EP1202746B1/en not_active Expired - Lifetime
- 2000-08-02 WO PCT/US2000/021021 patent/WO2001012227A1/en active IP Right Grant
- 2000-08-02 CA CA002380904A patent/CA2380904C/en not_active Expired - Fee Related
- 2000-08-02 PT PT00950930T patent/PT1202746E/pt unknown
- 2000-08-02 IL IL14791300A patent/IL147913A0/xx unknown
- 2000-08-02 EA EA200200246A patent/EA006876B1/ru not_active IP Right Cessation
- 2000-08-02 AU AU63959/00A patent/AU783116B2/en not_active Ceased
- 2000-08-02 NZ NZ517120A patent/NZ517120A/en unknown
- 2000-08-02 MX MXPA02001448A patent/MXPA02001448A/es active IP Right Grant
- 2000-08-11 AR ARP000104159A patent/AR029763A1/es not_active Application Discontinuation
-
2002
- 2002-02-11 NO NO20020663A patent/NO20020663L/no not_active Application Discontinuation
- 2002-02-11 ZA ZA200201156A patent/ZA200201156B/en unknown
- 2002-05-29 HK HK02104004.4A patent/HK1042244A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
PT1202746E (pt) | 2007-01-31 |
AR029763A1 (es) | 2003-07-16 |
ZA200201156B (en) | 2003-05-12 |
IL147913A0 (en) | 2002-08-14 |
AU6395900A (en) | 2001-03-13 |
JP2003507342A (ja) | 2003-02-25 |
CN1370080A (zh) | 2002-09-18 |
MXPA02001448A (es) | 2002-07-02 |
HUP0203162A2 (hu) | 2003-01-28 |
ATE341341T1 (de) | 2006-10-15 |
DK1202746T3 (da) | 2007-01-02 |
ES2272305T3 (es) | 2007-05-01 |
CA2380904C (en) | 2009-02-10 |
HUP0203162A3 (en) | 2006-07-28 |
NO20020663D0 (no) | 2002-02-11 |
CZ2002474A3 (cs) | 2003-02-12 |
EA200200246A1 (ru) | 2002-08-29 |
WO2001012227A1 (en) | 2001-02-22 |
NO20020663L (no) | 2002-04-09 |
CN1229142C (zh) | 2005-11-30 |
NZ517120A (en) | 2004-10-29 |
EP1202746B1 (en) | 2006-10-04 |
EP1202746A1 (en) | 2002-05-08 |
HK1042244A1 (zh) | 2002-08-09 |
DE60031127D1 (de) | 2006-11-16 |
KR20020018201A (ko) | 2002-03-07 |
DE60031127T2 (de) | 2007-02-01 |
EA006876B1 (ru) | 2006-04-28 |
AU783116B2 (en) | 2005-09-29 |
CA2380904A1 (en) | 2001-02-22 |
PL353267A1 (en) | 2003-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0013219A (pt) | Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto | |
NO20060398L (no) | Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft | |
EA200100572A1 (ru) | Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии | |
PT1286671E (pt) | Composicoes para o tratamento de cancro colorrectalque compreendem talidomida e irinotecan | |
CY1110894T1 (el) | Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης | |
NO20012774D0 (no) | Preparat og metode hvor det gjöres bruk av eteriske planteoljer | |
DK1169060T3 (da) | Natriumkanalblokkerpræparater og anvendelse deraf | |
BR0115427A (pt) | Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, e para prevenir a doença e o progresso da doença de alzheimer, e, uso de um composto | |
BR9805544A (pt) | Uso de um composto. | |
HUP0104688A2 (hu) | Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez | |
BRPI0415896A (pt) | combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia | |
BR0110506A (pt) | Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose | |
BR0108728A (pt) | Combinação farmacêutica terapêutica, e, método para tratar um c ncer. | |
DK1079843T3 (da) | Anvendelse af a1beta1 integrinreceptorinhibitorer og TFG beta1 inhibitorer til behandling af nyresygdom | |
BR0213181A (pt) | Combinações de inibidor de cox-2 | |
HK1080733A1 (en) | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol | |
BR9814419A (pt) | "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas" | |
BRPI0409473A (pt) | combinação de um inibidor de cox-2 e um agente antineoplásico do tipo alquilante para o tratamento de neoplasia | |
PL357179A1 (en) | Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers | |
EE200300057A (et) | Koostis vähi profülaktikaks ja raviks | |
BR0015121A (pt) | Composição farmacêutica utilizável para o tratamento de inflamação em humanos, e, método de tratamento de inflamação | |
BR0114856A (pt) | Combinação compreendendo camptotecina e um derivado de estilbeno para o tratamento de câncer | |
BR0310027A (pt) | Métodos de empregar uma combinação de uma 3-heteroaril-2-indolinona e um inibidor de ciclooxigenase-2 para o tratamento de neoplasia | |
SI1202746T1 (sl) | FARMACEVTSKA OBLIKA, KI VSEBUJE NSAID in ZAVIRALEC KINAZE EGFR, ZA ZDRAVLJENJE ALI PREPRECEVANJE POLIPOV DEBELEGA CREVESA IN KOLOREKTALNEGA RAKA | |
BR0315376A (pt) | Combinações de benzotiadiazóis e inibidores de cox-2 para o tratamento de dor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA:INT.CI. A61K 45/06, A61K 31/505, A61K 31/47, A61P 35/00 Ipc: A61K 45/06 (2011.01), A61K 31/505 (2011.01), A61K |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2138 DE 27/12/2011. |